1. Início
  2. Investigação Clínica
  3. Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503

Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503

Dados básicos

Código:
Ensaio Clínico Académico (INITIATE-HFrEF)
Protocolo:
Ensaio Clínico Académico (INITIATE-HFrEF)
EUDRACT:
2022-502409-14-00
NCT:
NCT05989503
Centro:
Dotação:
Ano de início:
2023
Ano de conclusão:
Ensaios clínicos Nacional Finan. Não Competitivo Privada

Objectivos do projeto

Ensaio Clínico – Iniciativa do Investigador; Fase: IV – Aleatorizado; Subtipo: Tratamento – Medicamento (de baixo nivel de intervenção); Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Multicêntrico – 4 Centros de Cuidados Secundários – Centros de Ensaio: CHUSJ/CHVNGE/CHUdSA/Hospital Pedro Hispano; Doença investigada: Insuficiência cardíaca – Participantes recrutados: 20

Documentos

  • Não há documentos

Participantes

Unidades de investigação

Stakeholders - Promotores

FMUP
Novartis

Outputs do ensaio clínico

LoRaWAN Based Street Lighting for Remote Areas with Shadow Zones

Proceedings Paper. 10.1109/MELECON56669.2024.10608473. 2024


A 4-variable model to predict cardio-kidney events and mortality in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study

Mendon?a, L.; (...); Ferreira, J.

Article. 10.1159/000533223. 2023


Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction.

Moreira-Costa, L; (...); Lourenço, AP

Article. 2024


Acute heart failure - an EFIM guideline critical appraisal and adaptation for internists

Article. 10.1016/j.ejim.2024.02.028. 2024

  • Open Access.

Acute heart failure - an EFIM guideline critical appraisal and adaptation for internists.

Article. 2024


Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure

Article. 10.1016/j.ijcard.2024.132477. 2024


AGE-STRATIFIED CARDIOVASCULAR RISK PROFILING USING SCORE2 AND SCORE2-OP MODELS

Meeting Abstract. 2024


An Analysis From a Tertiary Pediatric Hospital: Does Physical Activity Play a Role in the Management of Children and Young Adults With Osteogenesis Imperfecta?

Article. 10.7759/cureus.53646. 2024

  • Open Access.

Aortic stenosis rapid progression is associated with premature cardiac damage independently of baseline severity

Teixeira, R; (...); Fontes-Carvalho, R

Meeting Abstract. 2023


Author Correction: The European Reference Genome Atlas: piloting a decentralised approach to equitable biodiversity genomics.

Mc Cartney AM; (...); Mazzoni CJ

Correction. 10.1038/s44185-024-00065-3. 2024


Authors reply in response to a letter on "Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study"

Roncon Albuquerque, R.; (...); Paiva, JA

Letter. 10.1186/s13613-023-01215-9. 2023

  • Open Access.

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

Packer, M; (...); Anker, SD

Article. 10.1161/CIRCULATIONAHA.123.065748. 2023

  • Open Access.

Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial

Article. 10.1002/ejhf.3221. 2024

  • Open Access.

Body mass index effect on long-term survival after coronary artery bypass surgery: a competing risk analysis

Abreu, A; (...); Leite-Moreira, A

Article. 10.1093/icvts/ivad161. 2023

  • Open Access.

Can Breastfeeding Prevent Long-Term Overweight and Obesity in Children? A Population-Based Cohort Study

Article. 10.3390/nu16162728. 2024

  • Open Access.

Can Breastfeeding Prevent Long-Term Overweight and Obesity in Children? A Population-Based Cohort Study.

Article. 2024


Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme

Article. 10.1002/ejhf.3166. 2024


Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

Review. 10.1002/ehf2.15095. 2024


Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial

Article. 10.1002/ejhf.3478. 2024


Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial

Article. 10.1111/dom.15768. 2024

  • Open Access.

Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed

Editorial Material. 10.1016/j.cardfail.2023.12.002. 2024


Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed.

Article. 2024


Cardiovascular remodelling and reverse remodelling during pregnancy and postpartum: Looking at the right side

Ferreira A.F.; (...); Falcão-Pires I.

Article. 10.1016/j.preghy.2024.101171. 2024

  • Open Access.

Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling (vol 325, pg H774, 2023)

Correction. 10.1152/ajpheart.00200.2023_COR. 2024


Cardiovascular risk profile with SCORE2 and SCORE2-OP: comparing Portugal, Spain, Italy, and France using the new European predictive models

Article. 10.3389/fcvm.2024.1509240. 2024

  • Open Access.

Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF

Article. 10.1161/CIRCULATIONAHA.124.070553. 2024


Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study

Ferreira J.P.; (...); Leite-Moreira A.

Article. 10.1016/j.atherosclerosis.2024.117461. 2024

  • Open Access.

Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.

Article. 2024


Corrigendum: Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis(Front. Cardiovasc. Med., (2024), 11, (1407566), 10.3389/fcvm.2024.1407566)

Sousa Nunes F.; (...); Sousa C.

Correction. 10.3389/fcvm.2024.1471225. 2024

  • Open Access.

Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study

Gavina, C; (...); Taveira-Gomes, T

Article. 10.1002/clc.24183. 2023

  • Open Access.

Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.

Article. 2024


DISSECTING SEXUAL DIMORPHISM IN AORTIC VALVE STENOSIS BY PROTEOMICS

Meeting Abstract. 2024


Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?

Article. 10.1016/j.cardfail.2024.05.006. 2024


Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved

Article. 10.1002/ejhf.3136. 2024

  • Open Access.

Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF

Article. 10.1161/CIRCULATIONAHA.124.068774. 2024


Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials

Ferreira, JP; (...); Zannad, F

Article. 10.1002/ejhf.3101. 2023

  • Open Access.

Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

Article. 10.1038/s41440-024-01843-z. 2024

  • Open Access.

Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF

Article. 10.1016/j.jchf.2023.06.036. 2024

  • Open Access.

Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF.

Article. 2024


Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved

Article. 10.1002/jcsm.13393. 2024

  • Open Access.

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis

Article. 10.1002/ejhf.3180. 2024


Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes

Article. 10.3390/jcm13144113. 2024

  • Open Access.

Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes.

Article. 2024


Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort

Vasques-Nóvoa F.; (...); Friões F.

Article. 10.1007/s00392-024-02535-x. 2024

  • Open Access.

Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program

Article. 10.1002/ejhf.3078. 2024

  • Open Access.

Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program.

Article. 2024


Heart Failure in Brazil and the Need to Measure and Take Action

Editorial Material. 10.1016/j.cardfail.2023.10.485. 2024

  • Open Access.

Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure

Article. 10.1002/ehf2.15000. 2024

  • Open Access.

High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial

Article. 10.1016/j.cardfail.2023.11.020. 2024

  • Open Access.

High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.

Article. 2024


High-Caloric Diets in Adolescence Impair Specific GABAergic Subpopulations, Neurogenesis, and Alter Astrocyte Morphology.

Article. 2024


High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT

Article. 10.1016/j.ijcard.2024.131818. 2024

  • Open Access.

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.

Article. 2024


Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial

Article. 10.1016/j.repc.2023.05.013. 2024

  • Open Access.

Home- versus clinic-based exercise intervention in patients with heart failure (EXIT-HF trial): a pragmatic randomized controlled trial

Santos, M; (...); Ribeiro, F

Meeting Abstract. 2023


Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients

Brandao, M; (...); Ferreira, JP

Article. 10.55563/clinexprheumatol/ua087b. 2023


Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis

Article. 10.1111/dom.15572. 2024

  • Open Access.

Influence of iron deficiency definition on the efficacy of intravenous iron in heart failure: a meta-analysis of randomized trials

Article. 10.1007/s00392-024-02557-5. 2024

  • Open Access.

Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury

Article. 10.1186/s40635-024-00638-3. 2024

  • Open Access.

Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme

Article. 10.1002/ejhf.3227. 2024


Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?

Editorial Material. 10.1016/j.jchf.2024.01.011. 2024


Long-term cardiovascular outcomes in a population-based multicentric cohort of northern Portugal: Validation of the ESC/EAS prognostic risk classification

Article. 10.1016/j.jacl.2024.04.002. 2024


Long-term cardiovascular outcomes in a population-based multicentric cohort of northern Portugal: Validation of the ESC/EAS prognostic risk classification.

Article. 2024


Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial.

Article. 2024


MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Review. 10.1111/joim.13793. 2024

  • Open Access.

Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials

Article. 10.1159/000541686. 2024


Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients

Ferreira, JP, Rossello, X, Zannad, F

Editorial Material. 10.1002/ejhf.3098. 2023


Mineralocorticoid Receptor Antagonists in Heart Failure: An Update

Review. 10.1161/CIRCHEARTFAILURE.124.011629. 2024


Missed opportunities in the diagnosis of heart failure: a real-world assessment

Ferreira, JP; (...); Gavina, C

Article. 10.1002/ehf2.14531. 2023

  • Open Access.

National registries for rare clinical conditions: Networking to promote evidence-based healthcare

Leite-Moreira, AF, Saraiva, F

Editorial Material. 10.1016/j.repc.2023.03.007. 2023

  • Open Access.

Office- versus home-based evaluation of quality of life in heart failure with reduced ejection fraction: A randomized study

de Almeida Pinho I.; (...); Ferreira J.P.

Article. 10.1016/j.ijcard.2024.132341. 2024


Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial

Article. 10.1016/j.cardfail.2023.10.474. 2024

  • Open Access.

Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial.

Article. 2024


Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia

Editorial Material. 10.1016/j.jchf.2024.07.020. 2024


Perceptions of cardiology, professional preferences and impact on career choices among Portuguese cardiologists: Results from the Portuguese Society of Cardiology's Women and Cardiology Task Force survey

Article. 10.1016/j.repc.2023.07.004. 2024

  • Open Access.

Perceptions of cardiology, professional preferences and impact on career choices among Portuguese cardiologists: Results from the Portuguese Society of Cardiology's Women and Cardiology Task Force survey.

Article. 2024


Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.

Article. 2024


Polypill use for the prevention of cardiovascular disease: A position paper

Review. 10.1016/j.repc.2023.02.011. 2023

  • Open Access.

Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design - A population-based study

Baptista, R; (...); Gavina, C.

Article. 10.1016/j.repc.2023.10.004. 2023

  • Open Access.

Potential for organ donation after controlled circulatory death: a retrospective analysis

Article. 10.1097/j.pbj.0000000000000259. 2024


Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?

Ramos, P; (...); Pacheco-Figueiredo, L

Article. 10.1016/j.urolonc.2024.01.009. 2024


Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention

Santos-Ferreira, D; (...); Fontes-Carvalho, R

Article. 10.1007/s10554-023-02992-x. 2023

  • Open Access.

Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention.

Article. 2024


Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort

Article. 10.1002/ejhf.3202. 2024

  • Open Access.

Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there

Editorial Material. 10.1093/eurheartj/ehae399. 2024


Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program

Article. 10.1016/j.jacc.2024.07.013. 2024

  • Open Access.

REGIONAL AND COUNTRY-SPECIFIC VARIATIONS IN CARDIOVASCULAR RISK PROFILES: A REAL-WORLD ANALYSIS

Meeting Abstract. 2024


Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'

Editorial Material. 10.1002/ejhf.3415. 2024


Reply to the letter entitled “Inflammation in Heart Failure with Preserved Ejection Fraction: A Bystander or A Participant?” by Zhong M and Yan X

Letter. 10.1016/j.ijcard.2024.132278. 2024


Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis

Sousa Nunes F.; (...); Sousa C.

Review. 10.3389/fcvm.2024.1407566. 2024

  • Open Access.

Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France

Baudry, G; (...); Girerd, N

Article. 10.1002/ejhf.3103. 2023

  • Open Access.

Semaglutide and Cardiovascular Outcomes

Letter. 10.1056/NEJMc2400414. 2024


Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study

Gavina, C; (...); Taveria-Gomes, T

Article. 10.1016/j.atherosclerosis.2023.05.017. 2023

  • Open Access.

Sex-based differences and risk of recurrence in patients with atrial fibrillation undergoing pulmonary vein isolation

Aguiar-Neves, Ines; (...); Fontes-Carvalho, Ricardo

Article. 10.1016/j.ijcard.2024.132161. 2024


Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?

Article. 10.1016/j.jacc.2024.06.026. 2024


Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study

Roncon Albuquerque, R.; (...); Paiva, J.

Article. 10.1186/s13613-023-01185-y. 2023

  • Open Access.

Stretch-induced compliance mechanism in pregnancy-induced cardiac hypertrophy and the impact of cardiovascular risk factors

Ferreira A.F.; (...); Falcão-Pires I.

Article. 10.1152/ajpheart.00701.2023. 2024


Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort

Article. 10.1007/s00392-024-02548-6. 2024

  • Open Access.

TARGETING PREMATURE AGING TO IMPROVE HFPEF

Silva, E. D.; (...); Nascimento, D. S.

Meeting Abstract. 2023


The European Reference Genome Atlas: piloting a decentralised approach to equitable biodiversity genomics.

Mc Cartney AM; (...); Mazzoni CJ

Article. 10.1038/s44185-024-00054-6. 2024


The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes A Meta-Analysis of Randomized Placebo-Controlled Trials

Article. 10.2215/CJN.0000000584. 2024


The win ratio in cardiology trials: lessons learnt, new developments, and wise future use

Review. 10.1093/eurheartj/ehae647. 2024

  • Open Access.

Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE

Article. 10.1002/ejhf.3369. 2024


Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial

Article. 10.1002/ejhf.3218. 2024

  • Open Access.

Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Article. 10.1016/j.jchf.2024.08.020. 2024

  • Open Access.

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

Article. 10.1136/heartjnl-2023-323796. 2024

  • Open Access.

Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial

Khan, MS; (...); Butler, J

Article. 10.1016/j.cardfail.2023.06.024. 2023

  • Open Access.

Campos de estudo

Partilhar